skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

ファーマインテリジェンスはInforma PLCのインフォーマインテリジェンス部門の一部です

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon レポートストアメルマガ登録製品ログインProductLogin
Global Search Configuration
  • Close Icon

Introduction

Around 330,000 patients with mild cognitive impairment or mild to moderate Alzheimer’s disease will receive immunotherapies annually by 2021, allowing the treatment of this disease to reach an entirely new audience. This is just one catalyst contributing to the market value doubling in size over 2012-21. Datamonitor Healthcare has used a patient based approach to size the commercial potential of Alzheimer’s disease across the US, Japan and five major EU market. 

How will our Alzheimer’s disease forecast report benefit you?

  • Gain competitive insight
    Access an in-depth patient based report that details individual drugs in each disease setting via sales values and patient value, allowing you to assess your product positioning against those with the highest commercial value.
  • Prepare for market change
    Understand how the growing treated population within the Alzheimer’s market will change due to a shift in the diagnosing timeline over the forecast period to establish where you should be targeting new product developments.
  • Benchmark your product
    Understand how two new emerging product classes, 5-HT6 receptor antagonists and alpha-7 nAChR agonists, will compete against and complement existing market products, to help benchmark your product against new emerging classes and identify where your product will fit within the new market.
  • Identify investment opportunities
    See how potential disease modifying therapies, such as solanezumab the one pipeline drug suited to treat early stage patients, perform in various stages of Alzheimer’s disease, to help you identify any unmet needs within the early stages of the disease.

Key questions answered

  • How does the value of treating each stage of Alzheimer’s disease progress over the next decade and which factors are contributing to this?
  • How will Pfizer/Eisai’s Aricept, formerly the highest selling brand in the market, perform with the emergence of generic competition?
  • Which developmental products will emerge from the pipeline and what are their commercial potentials?
  • How does the Alzheimer’s disease market differ in each major region and which events will influence their future direction?

おすすめのニュース＆レポート

;

お問い合わせ＆レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

＊一部のサービスでは無料トライアルをご利用になれません。

デモに申込む

ご質問等ございましたらお気軽にご連絡下さい。

日本（平日：9時～18時）
電話：+81 (0)3 6273 4260
Email：inquiry.jp@informa.com

General enquiry

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。

レポートストア